Estimation of the marginal survival time in the presence of dependent competing risks using inverse probability of censoring weighted (IPCW) methods

Pharmaceutical Statistics

Volumn 7, Issue 3, 2008, Pages 202-214

  Matsuyama, Yutaka ^a   Yamaguchi, Takuhiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cause of failure; Competing risks; Cox proportional hazards model; Inverse weighting methods; Kaplan Meier estimator; Survival analysis

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; PRAVASTATIN;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; INVERSE PROBABILITY OF CENSORING EIGHTED METHOD; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; SURVIVAL; SURVIVAL TIME;

CLINICAL TRIALS AS TOPIC; HUMANS; PROBABILITY; RISK FACTORS; SURVIVAL RATE;

EID: 52649155146     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.290     Document Type: Article

References (32)

1. The Kyushu Lipid Intervention Study Group. A coronary primary intervention study of Japanese men: study design, implementation and baseline data. Journal of Atherosclerosis and Thrombosis 1996; 3:95-104.
2. The Kyushu Lipid Intervention Study Group. Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. Journal of Atherosclerosis and Thrombosis 2000; 7:110-121.
3. Gail M. A review and critique of some models used in competing risk analysis. Biometrics 1975; 31: 209-222.
4. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data (2nd edn). Wiley: New York, 2002.
5. Tsiatis AA. A nonidentifiability aspect of the problem of competing risks. Proceedings of the National Academy of Sciences 1975; 72:20-22.
6. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53:457-481.
7. Benfante R, Yano K, Hwang LJ, Curb D, Kagan A, Ross W. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men: implications of shared risk. Stroke 1994; 25:814-820.
8. Peterson AV. Bounds for a joint distribution function with fixed subdistribution functions: applications to competing risks. Proceedings of the National Academy of Sciences 1976; 73:11-13.
9. Slud EV, Rubinstein LV. Dependent competing risks and summary survival curves. Biometrika 1983; 70:643-649.
10. Klein JP, Moeschberger ML. Bounds on net survival probabilities for dependent competing risks. Biometrics 1988; 44:529-538.
11. Zheng M, Klein JP. Estimates of marginal survival for dependent competing risks based on an assumed copula. Biometrika 1995; 82:127-138.
12. Robins JM. Information recovery and bias adjustment in proportional hazards regression analysis of randomized trials using surrogate makers. American Statistical Association Proceedings of the Biopharmaceutical Section 1993; 24-33.
13. Robins JM, Rotnitzky A, Zhao LP. Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. Journal of the American Statistical Association 1995; 90:106-121.
14. Robins JM, Finkelstein DH. Correcting for non-compliance and dependent censoring in an AIDS clinical trial with Inverse Probability of Censoring Weighted (IPCW) log-rank tests. Biometrics 2000; 56:779-788.
15. Scharfstein DO, Robins JM. Estimation of the failure time distribution in the presence of informative censoring. Biometrika 2002; 89:617-634.
16. Robins JM. Causal inference from complex longitudinal data. Latent variable modeling and application to causality, Berkane M (ed.). Springer: New York, 1997; 69-117.
17. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55.
18. Horvitz DG, Thompson DJ. A generalization of sampling without replacement from a finite universe. Journal of the American Statistical Association 1952; 47:663-685.
19. Satten GA, Datta S. The Kaplan-Meier estimator as an inverse-probability-of-censoring weighted average. The American Statistician 2001; 55: 207-210.
20. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium in Mathematical Statistics and Probability. University of California Press: Berkeley, 1976; 221-233.
21. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. Journal of the American Statistical Association 1989; 84:1074-1078.
22. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560.
23. Robins JM. Marginal structural models versus structural nested models as tools for causal inference. Statistical Models in Epidemiology, the Environment, and Clinical Trials, Halloran ME Berry DA (eds). Springer: New York, 1999; 95-133.
24. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology 2003; 14:680-686.
25. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 1988; 16:1141-1154.
26. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999; 94: 496-509.
27. Anderson PK, Abildstrom SZ, Rosthoj S. Competing risks as a multi-state model. Statistical Methods in Medical Research 2002; 11:203-215.
28. Anderson PK, Keiding N. Multi-state models for event history analysis. Statistical Methods in Medical Research 2002; 11:91-115.
29. Tsiatis AA. Competing risks. Encyclopedia of Biostatistics, vol. 1, Armitage M, Colton T (eds). Wiley: New York, 1997; 824-834.
30. Crowder MJ. Classical Competing Risks. Chapman & Hall/CRC: London, 2001.
31. Scharfstein DO, Robins JM, Eddings W, Rotnitxky A. Inference in randomized studies with informative censoring and discrete time-to-event endpoints. Biometrics 2001; 57:404-413.
32. Joffe MM, Hoover DR, Jacobson LP, Kingsley L, Chmiel JS Visscher BR, Robins JM. Estimating the effect of zidovudine on kaposi's sarcoma from observational data using a rank preserving structural failure-time model. Statistics in Medicine 1998; 17:1073-1102.